Last updated on July 2018

Open-label Clinical Trial of Lacosamide in ALS


Brief description of study

Lacosamide is administered for patients with amyotrophic lateral sclerosis (ALS).

Detailed Study Description

Lacosamide is administered for patients with amyotrophic lateral sclerosis (ALS). This clinical trial is open-label, single group and before and after comparison study. Dosage of lacosamide is increased from 100mg to 400mg for 4 weeks. Safety of lacosamide administration in ALS is primary endpoint. Nerve excitability, fasciculation and muscle cramp are investigated before and after administration for secondary endpoints.

Clinical Study Identifier: NCT03186040

Contact Investigators or Research Sites near you

Start Over

Kazumoto Shibuya, MD, PhD

Chiba University Hospital
Chiba, Japan
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.